Abraham, C., & Cho, J. H. (2019). Inflammatory bowel disease.

New England Journal of

Medicine, 380(6), 546-558.

Boonyaratanakornkit, J., & Taylor, B. J. (2019). Isolation and fusion of B-lymphocytes with

myeloma cells to create hybridomas for monoclonal antibody production. Methods in

Molecular Biology, 1904, 15-23. doi:10.1007/978-1-4939-8964-9_2

Cheon, J. H., Kim, J. S., Kim, J. M., et al. (2012). Mechanism of action of TNBS as a hapten.

Journal of Immunology, 188(4), 2020-2027.

Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., ... & Schmidt, H.

H. (2018). Transcription factor NRF2 as a therapeutic target for chronic diseases: a

systems medicine approach. Pharmacological reviews, 70(2), 348-383.

Danese, S., & Fiorino, G. (2024). Biologic agents for IBD: Practical insights for the clinic.

Nature Reviews Gastroenterology & Hepatology, 11(10), 537-545.

Dmochowska, N., Wardill, H. R., & Bowen, J. M. (2018). The efficacy of novel treatments for

IBD. Journal of Gastroenterology and Hepatology, 33(6), 1127-1137.

Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J. F., Sandborn, W. J., ... &

Thakkar, R. B. (2016). Vedolizumab as induction and maintenance therapy for Crohn's

disease. New England Journal of Medicine, 375(20), 1946-1960.

Feuerstein, J. D., Cheifetz, A. S., & Chablaney, S. (2019). Immunogenicity of biologic therapies

in inflammatory bowel disease: A systematic review. The American Journal of

Gastroenterology, 114(4), 607-618.

Fiorino, G., Bonovas, S., Danese, S., & Peyrin-Biroulet, L. (2019). Biologic therapies in

inflammatory bowel disease: Practical insights. Nature Reviews Gastroenterology &

Hepatology, 16(10), 537-545.

Griffiths, A. M., Bukhari, M., El-Matary, W., Naviglio, S., Reinisch, W., Ricciuto, A., Van

Assche, G., Walters, T. D., & Church, P. C. (2020). Targeting TNF-α in inflammatory

bowel diseases with monoclonal antibodies. Gastroenterology, 158(2), 337-346.

doi:10.1053/j.gastro.2019.10.054

Halligan, A., Jacob, M., & Becker, C. (2019). Review article: The physiology of altered bowel

habit and defaecation in irritable bowel syndrome. Alimentary Pharmacology &

Therapeutics, 49(4), 362-376.

Hughes, P. A., Zola, H., Penttila, I. A., Blackshaw, L. A., Andrews, J. M., & Krumbiegel, D.

(2019). Immune activation in irritable bowel syndrome: Can neuroimmune interactions

explain symptoms? American Journal of Gastroenterology, 114(2), 250-256.

Hui, G., Wright, D. W., & Ng, P. M. L. (2019). Structure and function of antibodies. In S.

Dubinett & A. Sharma (Eds.), Cancer Immunotherapy (pp. 3-26). Springer, Cham.

doi:10.1007/978-3-030-01228-2_1

Jaggi, A. S., Bali, A., Singh, N., et al. (2014). Inflammatory mediators involved in TNBS-

induced colitis. Inflammopharmacology, 22(4), 209-217.

Jang, S., Kim, Y. J., Lim, S. M., & Kim, B. K. (2021). Mechanism of action of monoclonal

antibodies targeting TNF-α in Crohn’s disease. Gut Microbes, 13(1), 1-14.

doi:10.1080/19490976.2021.1946297
Kawada, M., Arihiro, A., Mizoguchi, E., et al. (2017). Use of ethanol as a vehicle for TNBS

administration and its role in mucosal barrier disruption. Digestive Diseases and

Sciences, 62(2), 286-296.

Khalili, H., Håkansson, N., Chan, S. S. M., et al. (2020). Adherence to a Mediterranean diet is

associated with a lower risk of later-onset Crohn's disease: Results from two large

prospective cohort studies. Gastroenterology, 158(6), 1673-1680.

Khor, B., Gardet, A., & Xavier, R. J. (2019). Genetics and pathogenesis of inflammatory bowel

disease. Nature Reviews Immunology, 19(7), 384-400.

Kobayashi, T. (2017). Prednisolone. Kawasaki Disease: Current Understanding of the

Mechanism and Evidence-Based Treatment, 181-185.

Kondo, T., Kawai, T., Tezuka, T., et al. (2019). Risk factors for the onset and progression of

Crohn's disease: A systematic review and meta-analysis of population-based

observational studies. Biomedicine & Pharmacotherapy, 109, 1700-1713.

Kumar, P., Banik, B., & Garg, G. (2018). Mechanism of action of monoclonal antibodies in

blocking antigen function and inducing ADCC. Current Drug Targets, 19(3), 232-245.

doi:10.2174/1389450118666170709143542

Levin, A. D., Wildenberg, M. E., van den Brink, G. R., et al. (2016). Mechanisms of action of

monoclonal antibodies in inflammatory bowel disease. Journal of Crohn's and Colitis,

10(8), 989-997. doi:10.1093/ecco-jcc/jjw066

Levine, A., Sigall Boneh, R., & Wine, E. (2018). Evolving role of diet in the pathogenesis and

treatment of inflammatory bowel diseases. Gut, 67(9), 1726-1738.

Lewis, J. D., Chuai, S., Nessel, L., et al. (2021). Use of the noninvasive markers in inflammatory

bowel disease. American Journal of Gastroenterology, 116(3), 203-217.

Masaar, K., Afzal, N., & Zia, K. (2019). Inflammatory bowel disease: Pathogenesis, diagnosis,

and current therapy. Journal of Gastroenterology and Hepatology Research, 8(3), 325-

330.

Megha, K., & Mohanan, P. (2021). Immunoglobulin: Structure, function, and its types.

International Journal of Science and Research, 10(7), 126-130. Retrieved from

https://www.ijsr.net

Michlewska, S. (2011). Tumor necrosis factor (TNF) and regulation of TNF receptor.

Inflammation Research, 60(9), 1095-1106. doi:10.1007/s00011-011-0393-2

Möllmann, H., Baibach, S., Hochhaus, G., Barth, J., & Derendorf, H. (2019). Pharmacokinetic-

pharmacodynamic correlations of corticosteroids. In Handbook of

pharmacokinetic/pharmacodynamic correlation (pp. 323-362). CRC Press.

Ng, S. C., Shi, H. Y., Hamidi, N., et al. (2015). Worldwide incidence and prevalence of

inflammatory bowel disease in the 21st century: A systematic review of population-based

studies. The Lancet, 390(10114), 2769-2778.

Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., ... & Kaplan,

G. G. (2017). Worldwide incidence and prevalence of inflammatory bowel disease in the

21st century: a systematic review of population-based studies. The Lancet, 390(10114),

2769-2778.
Parray, H. A., Chiranjivi, A. K., Asthana, S., Yadav, N., Shrivastava, T., & Kumar, H. (2020).

Production and purification of monoclonal antibodies from hybridoma cells. Methods in

Molecular Biology, 2070, 145-154. doi:10.1007/978-1-0716-0111-7_11

Peyrin-Biroulet, L., Loftus, E. V. Jr., Colombel, J. F., & Sandborn, W. J. (2019). The natural

history of adult Crohn's disease in population-based cohorts. American Journal of

Gastroenterology, 114(4), 581-589.

Posner, S. M., Moore, A. B., Williams, D. J., & Park, J. W. (2019). Monoclonal antibodies in

the treatment of inflammatory bowel disease. Journal of Clinical Gastroenterology, 53(7),

476-484.

Ramamoorthy, S., & Cidlowski, J. A. (2016). Corticosteroids: mechanisms of action in health

and disease. Rheumatic Disease Clinics, 42(1), 15-31.

Ranasinghe, I. R., & Hsu, R. (2023). Crohn Disease. 2023 Feb 20. StatPearls [Internet]. Treasure

Island (FL): StatPearls Publishing.

REFERENCES

Reider, S. J., Bernstein, C. N., Dubinsky, M. C., et al. (2019). The impact of cannabis and

cannabinoids for medical conditions on irritable bowel syndrome. Gastroenterology,

155(2), 545-554.

Roda, G., Chien Ng, S., Kotze, P. G., Argollo, M., Panaccione, R., Spinelli, A., ... & Danese, S.

(2020). Crohn’s disease. Nature Reviews Disease Primers, 6(1), 22.

Rodrigues, S. D. O., Cunha, C. M. C. D., Soares, G. M. V., Silva, P. L., Silva, A. R., &

Goncalves-de-Albuquerque, C. F. (2021). Mechanisms, pathophysiology and currently

 proposed treatments of chronic obstructive pulmonary disease. Pharmaceuticals, 14(10),

979.

Sadeghalvad, M., & Rezaei, N. (2021). Monoclonal antibodies (mAbs): A review of production,

types, mechanisms, and therapeutic applications. Journal of Clinical Immunology, 41(5),

927-939. doi:10.1007/s10875-021-01121-4

Stoker, J., Taylor, S. A., & Halligan, S. (2019). Imaging of colorectal cancer. Cambridge

University Press, 4(11), 208-214.

Talley, N. J., Abreu, M. T., Achkar, J. P., et al. (2018). An evidence-based systematic review on

medical therapies for inflammatory bowel disease. American Journal of

Gastroenterology, 113(5), 659-679.

Taylor, K., Schoenfeld, P., & Johnson, D. A. (2019). Crohn's disease practice guidelines: The

American College of Gastroenterology. American Journal of Gastroenterology, 112(4),

48-53.

Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn's disease. The

Lancet, 389(10080), 1741-1755.

Toruner, M., Loftus, E. V. Jr., Harmsen, W. S., et al. (2019). Risk factors for opportunistic

infections in patients with inflammatory bowel disease. Gastroenterology, 152(5), 799-

806.

Travis, S. P., Stange, E. F., Lémann, M., et al. (2018). European evidence-based Consensus on

the management of ulcerative colitis: Current management. Journal of Crohn's & Colitis,

11(6), 769-784.
Trigo, J. R., Ochoa, B., Rocha, R. D., et al. (2013). Utilization of TNBS to induce colitis in

experimental animals. Journal of Animal Physiology and Animal Nutrition, 97(3), 457-

465.

Van Loo, G., & Bertrand, M. J. M. (2023). Mechanisms of action of anti-TNF monoclonal

antibodies in inflammatory diseases. Trends in Immunology, 44(1), 1-14.

doi:10.1016/j.it.2022.05.005

Veauthier, B., & Hornecker, J. R. (2018). Crohn's disease: Diagnosis and management.

American Family Physician, 98(11), 661-669.

von Haehling, S., & Anker, S. D. (2014). Prevalence, incidence and clinical impact of cachexia:

facts and numbers—update 2014. Journal of cachexia, sarcopenia and muscle, 5, 261-

263.

Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., ... & Brugha, T. S.

(2015). Global, regional, and national incidence, prevalence, and years lived with

disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a

systematic analysis for the Global Burden of Disease Study 2013. The lancet, 386(9995),

743-800.

Wang, L., Harrington, L., Trebicka, E., et al. (2014). Comparison of TNBS-induced colitis

(delayed-type hypersensitivity) with DSS colitis (epithelial barrier disruption). Gut

Microbes, 5(3), 334-341.

Wu, X., Yang, L., Zheng, J., Zhao, M., Zhang, J., Liu, Q., & Jiang, X. (2016). Identification and

targeting of specific antigens on target cells for monoclonal antibody therapy. Journal of

Immunotherapy, 39(2), 63-70. doi:10.1097/CJI.0000000000000102

Zhou, Y., Zhu, L., Zhou, B., & Wei, Y. (2021). Antibody-dependent cell-mediated cytotoxicity

(ADCC) and its role in immune response. Nature Reviews Immunology, 21(3), 151-162.

doi:10.1038/s41577-021-00538-2